Former FDA official Dr Joshua Sharfstein, MD, has proposed a new paradigm for the regulation of dietary supplements. The underlying shift would be a move from an attitude of “benefit versus risk” to one of “access with safety.”
Two cases of drug spiking in products purporting to be dietary supplements drew enforcement actions announced recently by the Food and Drug Administration. One case in Puerto Rico involves sex enhancement products, while another in Pennsylvania dealt...
The recent Bayer victory in its case with the FTC is a positive for industry, but it is not going to solve all of the industry’s FTC problems, says Dr Daniel Fabricant, CEO and Executive Director of the Natural Products Association.
The recent decision in the Bayer vs FTC case contains positive lessons and some points of caution for the industry, notably around what you need to substantiate claims and why FTC is not going away, says Steve Mister, President and CEO of the CRN.
The Bayer vs FTC case in the US District Court of New Jersey is full of lessons, including what does and does not constitute ‘competent and reliable scientific evidence’, and the importance of having experts who know the space.
UPDATED: NPA calls decision a "win for the industry and consumers"